Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 127

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma

Vyas, Monika, Hechtman, Jaclyn F., Zhang, Yanming, Benayed, Ryma, Yavas, Aslihan, Askan, Gokce, Shia, Jinru, Klimstra, David S., Basturk, Olca · 2020 · Modern Pathology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41379-019-0398-2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 33

  1. Honeyman, 2014, Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma, Science, 343, 1010, 10.1126/science.1249484 · DOI · Paper page
  2. Graham, 2015, DNAJB1-PRKACA is specific for fibrolamellar carcinoma, Mod Pathol, 28, 822, 10.1038/modpathol.2015.4 · DOI · Paper page
  3. Simon, 2015, Transcriptomic characterization of fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci USA, 112, E5916, 10.1073/pnas.1424894112 · DOI · Paper page
  4. Graham, 2018, Fibrolamellar Carcinoma: what is new and why it matters, Surg Pathol Clin, 11, 377, 10.1016/j.path.2018.02.006 · DOI
  5. Adsay, 1996, Intraductal oncocytic papillary neoplasms of the pancreas, Am J Surg Pathol, 20, 980, 10.1097/00000478-199608000-00007 · DOI · Paper page
  6. Basturk, 2016, The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes, Mod Pathol, 29, 1058, 10.1038/modpathol.2016.98 · DOI
  7. Wang, 2019, Intraductal oncocytic papillary neoplasms: clinical-pathologic characterization of 24 cases, with an emphasis on associated invasive carcinomas, Am J Surg Pathol, 43, 656, 10.1097/PAS.0000000000001226 · DOI
  8. Wang, 2018, Mass-forming intraductal neoplasms of the biliary tract comprise morphologically and genetically distinct entities (abstract), Mod Pathol, 31, 1927A
  9. Cheng, 2015, Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology, J Mol Diagn, 17, 251, 10.1016/j.jmoldx.2014.12.006 · DOI · Paper page
  10. Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol. 2017;2017. https://doi.org/10.1200/PO.17.00084. · DOI · Paper page
  11. Shen, 2016, FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing, Nucleic Acids Res, 44, e131, 10.1093/nar/gkw520 · DOI · Paper page
  12. Zheng, 2014, Anchored multiplex PCR for targeted next-generation sequencing, Nat Med, 20, 1479, 10.1038/nm.3729 · DOI · Paper page
  13. Benayed, 2019, High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden, Clin Cancer Res, 25, 4712, 10.1158/1078-0432.CCR-19-0225 · DOI · Paper page
  14. Askan, 2016, Expression of markers of hepatocellular differentiation in pancreatic acinar cell neoplasms: a potential diagnostic pitfall, Am J Clin Pathol, 146, 163, 10.1093/ajcp/aqw096 · doi:10.1093/ajcp/aqw096
  15. Reid, 2016, The DNAJB1-PRKACA chimera: candidate biomarker and therapeutic target for fibrolamellar carcinomas, Hepatology, 63, 662, 10.1002/hep.28307 · DOI
  16. Xu, 2015, Genomic analysis of fibrolamellar hepatocellular carcinoma, Hum Mol Genet, 24, 50, 10.1093/hmg/ddu418 · DOI · Paper page
  17. Engelholm, 2017, CRISPR/Cas9 engineering of adult mouse liver demonstrates that the Dnajb1-Prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma, Gastroenterology, 153, 1662, 10.1053/j.gastro.2017.09.008 · DOI
  18. Kastenhuber, 2017, DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci USA, 114, 13076, 10.1073/pnas.1716483114 · DOI · Paper page
  19. Dinh, 2019, MicroRNA-375 suppresses the growth and invasion of fibrolamellar carcinoma, Cell Mol Gastroenterol Hepatol, 7, 803, 10.1016/j.jcmgh.2019.01.008 · DOI
  20. Graham, 2016, FGFR1 and FGFR2 in fibrolamellar carcinoma, Histopathology, 68, 686, 10.1111/his.12799 · doi:10.1111/his.12799
  21. Graham, 2018, Fibrolamellar carcinoma in the carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion, Hepatology, 68, 1441, 10.1002/hep.29719 · DOI · Paper page
  22. Nakamura, 2015, Genomic spectra of biliary tract cancer, Nat Genet, 47, 1003, 10.1038/ng.3375 · DOI · Paper page
  23. Shibata, 2018, Molecular genomic landscapes of hepatobiliary cancer, Cancer Sci, 109, 1282, 10.1111/cas.13582 · DOI · Paper page
  24. Drilon, 2018, Response to ERBB3-Directed targeted therapy in NRG1-rearranged cancers, Cancer Disco, 8, 686, 10.1158/2159-8290.CD-17-1004 · DOI · Paper page
  25. Reid, 2016, Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis, Cancer Cytopathol, 124, 122, 10.1002/cncy.21627 · DOI
  26. Farhi, 1982, Ultrastructure of fibrolamellar oncocytic hepatoma, Cancer, 50, 702, 10.1002/1097-0142(19820815)50:4<702::AID-CNCR2820500414>3.0.CO;2-F · doi:10.1002/1097-0142(19820815)50:4<702::aid-cncr2820500414>3.0.co;2-f
  27. Thomson, 2002, Evidence of undiscovered cell regulatory mechanisms: phosphoproteins and protein kinases in mitochondria, Cell Mol Life Sci, 59, 213, 10.1007/s00018-002-8417-7 · DOI
  28. Ward, 2010, Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation, Mod Pathol, 23, 1180, 10.1038/modpathol.2010.105 · doi:10.1038/modpathol.2010.105
  29. Lin, 2018, Fibrolamellar Carcinoma: a concise review, Arch Pathol Lab Med, 142, 1141, 10.5858/arpa.2017-0083-RS · doi:10.5858/arpa.2017-0083-rs
  30. Basturk, 2016, Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas, Virchows Arch, 469, 523, 10.1007/s00428-016-2014-x · DOI
  31. Martin, 2002, Hepatic intraductal oncocytic papillary carcinoma, Cancer, 95, 2180, 10.1002/cncr.10934 · doi:10.1002/cncr.10934
  32. Lalazar, 2018, Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms, Semin Liver Dis, 38, 51, 10.1055/s-0037-1621710 · DOI · Paper page
  33. Kastenhuber, 2019, Road map for fibrolamellar carcinoma: progress and goals of a diversified approach, J Hepatocell Carcinoma, 6, 41, 10.2147/JHC.S194764 · DOI

Cited by

See all 127

Metadata

Authors
Vyas, M., Hechtman, J. F., Zhang, Y., Benayed, R., Yavas, A., Askan, G., Shia, J., Klimstra, D. S., & Basturk, O.
Venue
Modern Pathology
Publisher
Elsevier BV
Published
2020-04
Volume
33
Issue
4
Pages
648-656
ISSN
0893-3952
Cited by
127
References
4
Language
en
Licence
Funders
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41379-019-0398-2
The paper
Vyas, M., Hechtman, J. F., Zhang, Y., Benayed, R., Yavas, A., Askan, G., Shia, J., Klimstra, D. S., & Basturk, O. (2020). DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Modern Pathology. https://doi.org/10.1038/s41379-019-0398-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.